

December 3-5, 2019 | Boston, MA
www.microbiome-gba.com

REGISTER BY
SEPTEMBER 20
TO SAVE \$700



MICROBIOME MOVEMENT GUT-BRAIN AXIS

Discover & Clinically Validate Microbiome Gut-Brain Axis Pathways To Transform Treatment Strategies For Neurological Disorders



David Donabedian
Co-Founder, CEO &
Director
**Axial
Biotherapeutics**



Valerie Taylor
Department Chair of
Psychiatry & Scientist
**University of Calgary &
Hotchkiss Brain Institute**



Michael Zasloff
Founder, CEO & Chairman
Enterin, Inc



Nicole Polinski
Senior Associate Director, Research
Programs
**The Michael J. Fox Foundation
for Parkinson's Research**



Christopher Missling
President & CEO
Anavex Life Sciences



Melanie Maya Kaelberer
Post-Doctoral Fellow
**Bohorquez Lab, Duke
University**



Timothy Buie
Attending Gastroenterologist
Boston Children's Hospital



Ai-Ling Lin
Associate Professor
University of Kentucky

Proud to Partner With:



The definitive forum dedicated to helping pharmaceutical and healthcare sectors discover & clinically validate microbiome gut-brain axis pathways to transform treatment strategies for neurological disorders

Cutting-edge insights into microbiome gut-brain axis mechanisms in neurological disease development have been pivotal in rethinking symptom management and treatment strategies for neurological patients.

Underlying neuroinflammatory, enteroendocrine, neurotransmitter and metabolic pathways and their relation to the gut microbiome are being better understood to cater to the unmet medical needs in the neurological space.

However, significant challenges remain in establishing the causality of microbiome gut-brain science, translating it into the human setting and designing clinical trials that consider the multifactorial etiology of neurological and mental health conditions.

Returning for the third year, the **Microbiome Movement – Gut-Brain Axis Summit** is your opportunity to:

- Discover pioneering preclinical data implicating metabolic, immune-mediated and enteroendocrine pathways in CNS disease development
- Explore translational approaches that are moving microbiome gut-brain axis science from association to causation

- Learn about critical considerations for microbiome clinical trials in the neurological and mental health setting to inform symptom and treatment management
- Realize the potential of microbial profiles as a biomarker for patient stratification to maximize the efficacy of already existing drugs for neurological disease
- Uncover the untapped commercial opportunity held by nutritional and therapeutic products for neurological and mental health

There is no question that the current research and discovery efforts in the microbiome gut-brain axis space are critical for turning this previously untapped therapeutic opportunity into a commercial success.

Join us to crystallize microbiome gut-brain signalling pathways and develop the next generation of microbiome-targeted products for improved neurological and mental health outcomes.



Trish Kruk

Program Director

Microbiome Movement

Five Reasons to Attend




Discover cutting-edge research presented by **Duke University & Massachusetts General Hospital** on the mechanisms underlying functional connectivity of the vagus nerve and the GBA in autism




Explore R&D efforts on the potential use of vitamins to treat psychiatric disease and how early neurodevelopment can impact disease in later life with **Massachusetts Institute of Technology & University of Chicago**



Access the latest data on how to translate pre-clinical findings supporting the gut microbiome's role in neurological disease into therapeutic or nutritional targets with **4D Pharma & Symbiotix Biotherapies**



Harness the clinical experience of **Enterin, Anavex Life Sciences & Axial Biotherapeutics** to inform the design of neurotrials investigating microbiome-based therapeutics



Mobilize industry experience in securing funding and commercial partnerships with **The Michael J. Fox Foundation for Parkinson's Research & Holobiome** to make meaningful scientific progress

YOUR EXPERT SPEAKERS



Christopher Missling
President & CEO
Anavex Life Sciences



David Donabedian
Co-Founder, CEO & Director
Axial Biotherapeutics



Melanie Maya Kaelberer
Post-Doctoral Fellow
Bohorquez Lab, Duke University



Timothy Buie
Attending Gastroenterologist
Boston Children's Hospital



Michael Zasloff
Founder, CEO & Chairman
Enterin, Inc



Zain Kassam
Chief Medical Officer
Finch Therapeutics



Philip Strandwitz
Co-Founder & CEO
Holobiome



Peter Nara
Chief Scientific Officer & Founder
Keystone Bio



Alessio Fasano
Professor & Director Mucosal Immunology & Biology Research Center
Massachusetts General Hospital



Stephen Skolnick
Research Technologist
Massachusetts Institute of Technology



Rishab Shyam
Executive Director
PureTech Health



Ali Keshavarzian
Professor & Gastroenterologist
Rush University Medical Center



Frank Middleton
Associate Professor
SUNY Upstate Medical University



Nader Yaghoubi
Co-Founder & CEO
Symbiotix Biotherapies Inc



Nicole Polinski
Senior Associate Director, Research Programs
The Michael J. Fox Foundation for Parkinson's Research



Valerie Taylor
Department Chair of Psychiatry & Scientist
University of Calgary & Hotchkiss Brain Institute



Jing Lu
Research Professional
University of Chicago



Ai-Ling Lin
Associate Professor
University of Kentucky



Speaker TBC
4D Pharma

I'm excited to share the knowledge of the role of gut microbiota-brain axis in Parkinson's Disease pathogenesis and therapy

Ali Keshavarzian, Rush University Medical Center, Confirmed Speaker

CONFERENCE DAY ONE WEDNESDAY, DECEMBER 4

7.20 Registration & Morning Coffee

8.20 Chairperson Opening Remarks

Gut Instincts - Reviewing the Potential of Microbiome Science in GBA-Related Disease Settings

Session Purpose:

The microbiome gut-brain axis space is at a critical point of establishing causality and application in the pharmaceutical and healthcare settings. This theme will review the current thinking towards approaches in understanding the role of the microbiome in gut-brain axis signalling and how this knowledge can be applied to shape drug development and healthcare practice in the GBA space.

8.30 Microbiome GBA Industry & Academic Leaders Panel Discussion – Providing an Overview of the Status & Direction of the Microbiome GBA Space

- Providing a bird's eye view on scientific and product development progress made in the microbiome gut-brain axis space – what is the status of this field?
- Reviewing gaps in our knowledge of neurogastroenterology and hot pockets of innovation opportunity in the microbiome-GBA space
- Plotting the road to success: what is our end goal, applications of R&D efforts and what hurdles must be overcome to get there?
- The role of public/private collaborations and investment opportunities in the microbiome-GBA field – who can you partner with for funding to support and accelerate your research?
- If we could change one thing today, what would it be?



David Donabedian
Co-Founder, CEO &
Director
Axial
Biotherapeutics



Timothy Buie
Attending
Gastroenterologist
Boston Children's
Hospital



Valerie Taylor
Department Chair of
Psychiatry & Scientist
University of
Calgary & Hotchkiss
Brain Institute



Michael Zasloff
Founder, CEO &
Chairman
Enterin, Inc

It's A Two Way Street! Exploring Signalling Pathways in the Microbiome-Gut-Brain Axis

Session Purpose:

The mechanisms of action underlying the microbiome-gut-brain axis remain unclear. This theme aims to elucidate the ongoing research and development efforts that are increasing our knowledge of the microbe-microbe, host-microbe and immune system-microbiome interactions that influence the bidirectional signalling superhighway that is the gut-brain axis.

Melanie Maya
Kaelberer
Post-Doctoral Fellow
Bohorquez Lab,
Duke University

9.30 The Gut-Brain Connection: Functional Connectivity of the Vagus Nerve

- Neuropod cells are the epithelial sensory transduction cells of the gut
- Neuropod cells synapse with vagal neurons
- Glutamate is a neurotransmitter for fast synaptic communication with the vagus nerve

Stephen Skolnick
Research
Technologist
Massachusetts
Institute of
Technology

10.00 Microbes & Monoamine: Stepping Stones from Dysbiosis to Psychiatric Disease

- The history and role of the microbiome in endogenous benzodiazepine synthesis; implications for anxiety
- How diet, antibiotics, and the microbiome influence the retention of dietary heavy metals, especially methylmercury
- A surprisingly simple model for the etiology of depression and schizophrenia, centered on a deficiency of queuine—a nearly unheard-of vitamin produced by the microbiome

10.30 Speed Networking & Morning Refreshments

Jing Lu Research Professional University of Chicago	11.30 Exploring the Early Microbiome & Neurodevelopment • Preterm infants differ from term infants in initial colonization and succession of microbiota due to host and environmental factors • Early microbiome of infants is a modifiable target that influences the postnatal outcomes including growth, brain development, and behaviours • The effect of early microbiome on blood-brain barrier development and functions might reveal a critical site of microbiome and brain interplay
Alessio Fasano Professor & Director Mucosal Immunology & Biology Research Center Massachusetts General Hospital	12.00 Microbiome and Gut-Brain Axis: The Autism Paradigm to Move from Association to Causation • Genetic predisposition and exposure to environmental triggers are necessary but not sufficient (as believed before) to develop Autism spectrum disorders (ASD); • Among additional components, an unbalanced gut microbiome (dysbiosis) is taking central stage as a possible element affecting the gut-brain axis communication, leading to neuroinflammation typical of ASD • However, many of the cross-sectional studies reported in literature are merely descriptive, since their design does not allow a mechanistic link between dysbiosis and pathogenesis of ASD. Birth cohort prospective, longitudinal studies are necessary to move from association to causation, so identifying possible therapeutic targets aimed at modifying gut microbiome composition and function to ameliorate neuroinflammation
Rishab Shyam Executive Director PureTech Health	12.30 Highlighting Important Highways Enabling Immune Crosstalk • Discussing immune modulation and the impact of the lymphatic axis on the gut-brain axis • Highlighting the gut and meningeal lymphatic architecture • Pinpointing opportunities to manipulate this cross talk (which is in essence what the microbiome is doing)
	13.00 Lunch & Networking

Harnessing –Omics Tools to Facilitate the Study of Microbial Function & Interactions at an Ecology Level

Session Purpose:

Widespread use of 16S sequencing and more readily available shotgun sequencing technologies have accelerated the identification and characterization of microbes with a key role in the gut-brain axis. However, we are at a critical point of really needing to understand microbial function in order to take research to the next level. This theme explores the –omic tools available to us and how these are being integrated with metabolomics to indicate microbial function at an ecology level and identify potential therapeutic targets.

Frank Middleton Associate Professor SUNY Upstate Medical University	14.00 Investigating Gut-Brain Interactions in Autism & Neurodegenerative Disorders • The resident microbiomes of the upper and lower GI tract are altered in autism and neurodegenerative disorders • We can monitor large-scale host-microbiome interactions • Changes in composition can lead to functional alterations that affect brain development and disease resistance
---	---

Translating Basic Microbiome Science into Therapeutic or Nutritional Targets Through Pre-Clinical Models

Session Purpose:

As our understanding of the microbiome gut-brain axis crystallizes, we can move beyond basic science and explore the therapeutic avenues that this opens. With a plethora of druggable targets at our disposition including microbes, metabolites and neurotransmitters to name but a few, this theme will consider how the therapeutic potential of these targets can be demonstrated in pre-clinical models and what technical translational challenges must be overcome.

Ai-Ling Lin
 Associate Professor
University of Kentucky

14.30 Dietary Inulin Alters the Gut Microbiome, Enhances Systemic Metabolism & Reduces Neuroinflammation in an APOE4 Mouse Model

- Carriers of the apolipoprotein ε4 allele (APOE4) develop systemic metabolic dysfunction decades before showing Alzheimer's disease (AD) symptoms; preserving metabolic function early on may be critical to reducing the risk for AD
- Here we show that prebiotic inulin increases beneficial gut microbiota, elevates short chain fatty acids, tryptophan-derived metabolites and bile acids, and reduces inflammatory gene expression in the brain in young, asymptomatic APOE4 transgenic mice
- Using a prebiotic diet to enhance systemic metabolism may be useful for reducing AD risk in asymptomatic APOE4 carriers

Ali Keshavarzian
 Professor &
 Gastroenterologist
Rush University Medical Center

15.00 Exploring the Role of Intestinal Microbiota & Gut-Derived Inflammation in Parkinson's Disease

- Changes in microbiota composition and function in PD
- Mechanism by which microbiota triggers microglia activation, neuro-inflammation and DA loss
- Role of microbiota-directed intervention in the treatment of PD

15.30 Afternoon Refreshments & Networking

Mastermind Session – Discussing the Therapeutic Potential of the Microbiome in Different Clinical Indications

Session Purpose:

This session will facilitate in-depth discussion amongst participants in an informal setting. After splitting into groups, participants will have the opportunity to discuss the potential of applying microbiome science in specific disease settings. Notes from this session will be shared with attendees after the meeting.

1. 16.00 Applying microbiome science in neurodegenerative disorders e.g. Alzheimer's disease

2. 16.00 Applying microbiome science in neurocognitive disorders e.g. autism

3. 16.00 Applying microbiome science in neuropsychiatric disorders e.g. schizophrenia

16.30 Chairperson's Closing Remarks

16.40 Evening Drinks Reception & Poster Session Hosted by the Microbiome Movement

CONFERENCE DAY TWO

THURSDAY, DECEMBER 5

	8.00 Registration & Morning Coffee
	8.50 Chairperson Opening Remarks
(Continuation of Yesterday's Theme) Translating Basic Microbiome Science into Therapeutic or Nutritional Targets Through Pre-Clinical Models	
Speaker TBC 4D Pharma	9.00 Microbiome-Derived Live Biotherapeutics to Target the Gut-Brain Axis • Overviewing 4D Pharma's MicroRx discovery platforms designed to specifically target neurodegenerative diseases such as Parkinson's Disease • Demonstrating preclinical data on how 4D Pharma LBP candidates affect gut-brain communication and how bacterial metabolites affect pathways involved in neuroinflammation, neuroprotection and neurodifferentiation • Sharing additional data on how specific LBPs can influence neuro-behavioural conditions such as autism spectrum disorders
Nader Yaghoubi Co-Founder & CEO Symbiotix Biotherapies Inc	9.30 TREG-modulating Therapeutics for the Treatment of Multiple Sclerosis • Symbiotix Biotherapies has been developing a novel class of molecular therapeutics based on molecules derived from gut microbiota • These molecules function via a first-in-class mechanism that results in activation of regulatory T cells, and we have been exploring therapeutic application to MS and other immune-mediated conditions • We have completed upstream and downstream process development for our lead program, SYMB-104, and are moving towards human clinical testing
Peter Nara Chief Scientific Officer & Founder Keystone Bio	10.00 Addressing Oral Systemic Inflammation via Precision Bio-therapeutic Pharmabiome Intervention Directed Against Porphyromonas gingivalis • A peripheral Keystone Pathogen is capable of establishing a dysbiotic altered microbiome • Keystone pathogens can significantly alter host responses and disease processes both locally and distally within the body • Targeted precision biotherapeutics to keystone pathogens may represent a novel and important means of ameliorating multiple disease conditions and allow for re-establishment of a more normal microbiome
	10.30 Networking & Morning Refreshments
Harnessing Clinical Experience to Inform In-Human Study Design & Microbiome-Based Product Development	
Session Purpose: Permeation of microbiome science into the healthcare and pharmaceutical industries has meant that more investigators are integrating the collection of microbiome samples throughout in-human clinical trials. However, in many cases this has been done retrospectively. This theme will harness clinical experience on how to design prospective trials that collect and analyze microbiome data, what to do with retrospectively collected microbiome data and considerations on microbiome v disease-specific endpoints so that you can plan a trial that has clinically relevant endpoints.	
Valerie Taylor Department Chair of Psychiatry & Scientist University of Calgary & Hotchkiss Brain Institute	11.00 Discussing Challenges in Clinical Trial Design - Lessons Learned from RCTs of Fecal Transplant in Mood Disorders • Overviewing the clinical evidence translating GBA work in to the area of mental health treatment • Discussing pragmatic challenges designing clinical trials targeting the GBA

Christopher Missling President & CEO Anavex Life Sciences	11.30 Sharing Clinical Data that Identifies Gut Microbiota Biomarkers Associated with Improved Clinical Response in Alzheimer's Disease Patients Treated with ANAVEX®2-73 • Linking high-levels of two gut microbiota families to improved responses with ANAVEX®2-73 • Outlining how and why ANAVEX®2-73 may have a beneficial homeostatic effect on brain-gut microbiota axis
Michael Zasloff Founder, CEO & Chairman Enterin, Inc	12.00 Clinical Experience of Targeting Alpha Synuclein in Enteric Nerves Produced in Response to Infection Over the Life Course to Treat Parkinson's Disease • Exploring the underlying pathogenic pathways linking alpha synuclein and the enteric nervous system resulting from the aggregate impact of infection over the life course • Demonstrating clinical activity of ENT-01 in the treatment of Parkinson's Disease • Ensuring clinical success – key takeaways for getting products into the clinic
	12.30 Lunch & Networking
David Donabedian Co-Founder, CEO & Director Axial Biotherapeutics	13.30 Clinical Study Design Considerations for the Testing of Gut Retentive Products, such as AB-2004, in the Neurological Disease Setting

Action Session – How Can We Transform the Way We Design Clinical Study Programs that are Investigating the Microbiome-GBA?

Session Purpose:

Interact with your peers in small groups in an 'Action' Session – we've heard about clinical case studies and had a chance to dig deeper and understand what has facilitated clinical progress so far. But what are we going to change when we get back to our organizations?

Output-Focused Action Session Facilitated by the Chair

14.00 What Will You Now Change About Your Approach to R&D Planning When the Ultimate End Goals are to Inform Clinical Investigation & Improve Patient Outcomes?

Highlighting Organizations that Provide Support to Projects Targeting the Microbiome Gut-Brain Axis

Session Purpose:

As we face the global public health challenge of an ageing population, it is vital to assess the funding opportunities to help turn microbiome gut-brain axis R&D into a clinical reality. The purpose of this theme is to highlight organizations that provide funding and support projects targeting the microbiome gut-brain axis.

Nicole Polinski
Senior Associate
Director, Research Programs
The Michael J. Fox Foundation for Parkinson's Research

14.30 Advancing Parkinson's Disease Research through Funding and Collaborative Team Building

- Overviewing the MJFF funding programs and additional resources MJFF provides to support Parkinson's disease research
- Highlighting our experience with building collaborative groups comprised of different stakeholders to move Parkinson's Disease research forward
- Touching on MJFF's involvement in Parkinson's disease-related microbiome studies and our current goals as they pertain to supporting this area of research

Speed Learning: R&D Setbacks & Leaps Forward from Research & Industry Leaders that are Shaking Up the Microbiome-GBA Space

Session Purpose:

Uncover the story behind setbacks and leaps forward from those conducting research and product development for gut-brain related disorders in a quick-fire session. Each table will be hosted by a Neurogastroenterology leader who will share the secrets of their most high-impact leap forward in microbiome GBA research and implications for biomarker identification, product development or public health policy. You then get the opportunity to question the host before moving on to the next table. Stories to be shared include:

1. 15.00 Learnings from A Commercial Product Development Journey in the Microbiome Gut Brain Axis Space



Zain Kassam
Chief Medical Officer
Finch Therapeutics

2. 15.00 Inspiring Cross-Functional Thinking in Mutli-Disciplinary Teams to Ensure Microbiome Gut-Brain Research Project Success

Session Leader TBC

3. 15.00 Building Partnerships/ Collaborations & Setting Expectations on Both Sides to Achieve R&D Goals



Phil Strandwitz
Co-Founder & CEO
Holobiome

15.45 **Chairperson's Closing Remarks**

16.00 **End of 3rd Microbiome Movement – Gut-Brain Axis Summit**

🦠 This conference has consistently proved to be an exceptional venue for the dissemination of progress in the field of the Gut-Brain-Axis from all stakeholders. I have always enjoyed interacting with the other attendees and learning of their advancements, as well as sharing ours. I look forward to doing so again this year 🦠

Philip Strandwitz, Holobiome, Confirmed Speaker

🦠 A great opportunity to share ideas, reach a new audience, and help shape the future of this exciting field! 🦠

Stephen Skolnick, Massachusetts Institute of Technology, Confirmed Speaker

PRE-CONFERENCE WORKSHOP

TUESDAY, DECEMBER 3

Pre-Conference Workshop

1.00-4.00pm

Friend or Foe? The Microbiome's Role in Metabolism of Existing Drugs for Neurological Disease

It is well known that the microbiome can influence the safety and efficacy of existing drugs for neurological disease through drug metabolism. However, we have not yet applied this knowledge fully to improve therapeutic outcomes for patients based on the impact of their microbiomes on treatment response or non-response.

This workshop will give you the opportunity to understand:

- The currently existing evidence for microbiome metabolism of existing drugs - what are the implications from recent evidence published on microbiota metabolism of L-Dopa, its bioavailability and role in manifestation of clinical side effects?
- Could this knowledge be used in clinical trial design to stratify patients based on microbiota composition or subtype?
- How the microbiome could be harnessed for improved therapeutic outcomes for patients

Workshop Leader



Ali Keshavarzian
Professor &
Gastroenterologist
Rush University Medical Center

Ali Keshavarzian, MD, FRCP, FACP, AGAF, MACG the Josephine M. Dyrenforth Chair of Gastroenterology, Professor of Medicine, Professor of Pharmacology, Molecular Physiology, Director of the Division of Digestive Diseases and Nutrition and Director of the Institute for Advanced Study of the Gut, Chronobiology and Inflammation at Rush University Medical Center in Chicago, Illinois has been a practicing gastroenterologist with a specialty in managing patients with inflammatory bowel disease for over 30 years. He trained in medicine at the Tehran University Medical School in Iran and residency and GI fellowship in England- at Guy's Hospital Medical School, Hillingdon Hospital and Hammersmith Hospital. After a year of GI research fellowship at the University of Maryland, School of Medicine in 1985, he held faculty positions at University of Maryland, Loyola University Medical Center and Rush University Medical Center in Chicago. He became the Chief, Section of Gastroenterology at Hines VA Hospital, Hines, IL in 1992, Director, Division of Digestive Disease and Nutrition at Loyola University Medical Center in Maywood, IL in 1995 prior to coming to Rush University Medical Center, Chicago IL in 1999 as the Director of the Division of Digestive Diseases and Nutrition.

As a clinician scientist Dr. Keshavarzian has been studying the impact of environmental factors (stress, alcohol, sleep and circadian disruption) on intestinal barrier function host/microbe interaction that promote intestinal and systemic (gut-derived)

inflammation leading to initiation and/or progression of inflammatory disorders including inflammatory bowel disease, irritable bowel syndrome, food allergy, metabolic syndrome, alcoholic and non-alcoholic steatohepatitis and Parkinson's disease. He has contributed to over 340 peer-reviewed published articles and book chapters with an h-index of 75. He has been doing basic science, translational and clinical research focused on liver and GI tract for almost three decades and the PI on multiple R01, R-21, RC3 and SBIR grants collaborating with many investigators. He was one of the first investigators to report the key role of oxygen free radicals in tissue injury in inflammatory bowel disease and alcohol-induced disruption of the intestinal barrier in alcoholic liver disease in the 1980s and one of the first investigators to begin to focus on the role of intestinal microbiota in health and disease in alcoholism, IBD, cancer, HIV and Parkinson. He has been studying the effects of circadian rhythm disruption on intestinal disease since 2007 and one of the early investigators to examine the effects of circadian disruption on the effects of alcohol and to report the negative impact of sleep and circadian disruption in IBD.

Dr. Keshavarzian was instrumental in starting the mentoring program at Rush University Medical Center and was honored with several Teaching and Service Awards and with the Excellence in Mentoring Award and continues to mentor at Rush, nationally and internationally. He is involved with numerous local/regional and national committees and gastroenterology associations and current reviewer for Medical Research Council of UK, NIH, Foundations, ACG and AGA research review panels. He has served in multiple ACG committees in the last three decades and was the ACG governor for the state of Illinois for two terms.

PARTNER WITH US

Microbiome gut-brain axis research is seeing an injection of scientific interest, collaborations and investment. Researchers, nutritional and therapeutic product developers are looking out for the most innovative service providers with experience in microbial genome sequencing and analysis, *in vitro* and *in vivo* model provision, study design in the neurological and mental health setting, contract manufacturing, as well as IP and regulatory consulting.

The **3rd Microbiome Movement – Gut-Brain Axis Summit** is the perfect opportunity to demonstrate your technology, experience and thought leadership to meet the increasing demands of this fast-growing field.

Why Partner?



Benefit from Market Intelligence

Microbiome gut-brain axis research opens the opportunity to develop a range of microbiome-targeted therapeutic or nutritional products to improve neurological and mental health outcomes. Hear how and where biotech companies are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly.



Raise Brand Awareness

Benefit from pre and post conference exposure to our microbiome and neurologic KOL community and increase market share through unique branding formats. Also, differentiate your pre-clinical, clinical or translational services from other solution providers.



Position Yourself as an Industry Expert

With the emergence of biotech and nutritional companies developing microbiome-targeted products for neurological and mental health, followed by interest shown from investors and therapeutic companies, this meeting is a dedicated platform to put your independent expertise in front of the key decision makers in the field.



Meet and Network with Industry Pioneers


With a room full of microbiome and neuroscience specialists, as well as microbiome-targeted product developers looking to see how they can harness neurogastroenterology, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.



Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

Seniority



C-level: 27%


**President/VP/
Manager: 14%**

Director/Manager: 33%

**Principal Scientist/Lead
Investigator: 16%**

**Professor/Associate
Professor: 10%**

Company by Type



*Statistics based on the Microbiome Movement – Gut-Brain Axis Summit 2018

GET INVOLVED



Matthew Ashman

Partnerships Director

Tel: +44 (0) 203 8540 224

Email: partner@microbiome-movement.com

PROUD TO PARTNER WITH



Exhibition Partner

Quay Pharmaceuticals is a privately owned CDMO working from FDA and MHRA inspected facilities. We are licensed to formulate and manufacture the finished dosage forms for live biotherapeutics as well as small and large molecules. In the live biotherapeutic space we work with consortia and single strains for drug delivery in oral and topical formats. Working as part of your team we rapidly and effectively bring products through development to First In Human studies to deliver success.

www.quaylivebio.com



Event Partner

Boston Analytical is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2005 accredited world class pharmaceutical testing laboratory. We provide identity, purity, and potency analyses necessary to characterize microbiome products and we have a proven track record on a variety of Microbiome programs including Spore Fraction and Defined Drug Product manufacturing processes. Boston Analytical employs LabWare Inc.'s™ LIMS and ELN software to help ensure on-time and accurate results.

www.bostonanalytical.com

!!! There is considerable utility in defining the changes in the microbiome that are occurring in different disease states and body niches. Although most scientists and physicians were never trained to consider the microbiome in their research, it is undeniable how much can be learned from a comprehensive approach that integrates this information with other disciplines !!!

Frank Middleton, SUNY Upstate Medical University, Confirmed Speaker

!!! A great chance to learn about advances in the complex interactions between the gut and brain, get a better idea of alternate ways of studying a dysbiotic gut microbiome and learn about ways to treat and modify the abnormal gut microbiome for improved brain health !!!

Peter Nara, Keystone Bio, Confirmed Speaker

JOIN THE MICROBIOME MOVEMENT



February 2020: Paris, FR
microbiome-europe.com

 The event organization and content was flawless. This is a premier event for the microbiome biotech and pharma industry. 

Jim Brown, Senior Fellow Director in Computational Biology, GSK



February 2020: Raleigh, NC
microbiome-agbiotech.com

 Possibly the best conference in the agricultural microbiome space - a great mix of basic scientific research and product development from universities, multinationals and start-up companies. Congratulations! 

Marcus Meadows-Smith, CEO, BioConsortia



May 2020: Boston, MA
microbiome-infant-health.com

 This is great opportunity to learn and connect with thought leaders who are on the forefront in the emerging areas of maternal and infant microbiome health. 

Noah Voreades, Consultant, GenBiome Consulting



June 2020: Boston, MA
microbiome-summit.com

 This meeting is possibly the best in the microbiome field for a biotech company, for networking and hearing the latest developments. 

Mike Romanos, CEO, Microbiotica



July 2020: San Diego, CA
microbiome-dermatology.com

 This meeting was the perfect balance between basic/applied science and academic/commercial interests. 

Greg Hillebrand, Senior Principal Research Scientist, Amway



September 2020: Singapore
microbiome-movement-asia.com

 The microbiome is one of the most emerging fields right now and at this meeting we have the group leaders and industry pioneers in the field of microbiome science and knowledge. 

Yogesh Mudalier, Research Investigator - Formulation Development, Takeda



October 2020: St. Louis, MO
microbiome-animal.com

 I really enjoyed meeting critical innovators within animal health and learn more about how technologies within this space and developing and the key problems being addressed. 

Megan Lyman, Director, IP, Regulatory & Product Development, AgTech Accelerator



November 2020: Boston, MA
microbiome-nutrition.com

 If you want to learn about the latest developments and mix with the movers and shakers in the industry, you HAVE to be there. 

Alan Murray, CEO, NextFoods Inc



December 2019: Boston, MA
microbiome-gba.com

 It is one of the best meetings I've been to! Great job! 

Yanjiao Zhou, Research Scientist, The Jackson Laboratory

3 EASY WAYS TO BOOK



www.microbiome-gba.com



Tel: +1 617 455 4188



Email: register@hansonwade.com

Please email info@microbiome-movement.com for any further information on location updates

TOP 3 REASONS TO ATTEND:

- 1 Explore novel approaches that are harnessing microbiome-GBA science to develop therapeutic products that improve patient health outcomes
- 2 Learn from the expertise of key opinion leaders and discover pioneering case studies that showcase pre-clinical, translational and clinical data supporting the role of microbiome-GBA axis in neurological disorders
- 3 Uncover and forge collaborations you need with research and commercial leaders across the microbiome-GBA field to accelerate your research and product development efforts towards the market place

SECURE YOUR PLACE

Industry Pricing	Register & Pay By Friday, September 20	Standard Pricing
Conference + 1 Workshop	\$2298 (save \$700)	\$2898 (save \$100)
Conference Only	\$1799 (save \$600)	\$2399
Workshop Only	\$599	

Start Up, Academic & Not-For-Profit Pricing	Register & Pay By Friday, September 20	Standard Pricing
Conference + 1 Workshop	\$1398 (save \$700)	\$1998 (save \$100)
Conference Only	\$1099 (save \$600)	\$1699
Workshop Only	\$399	

Team Discounts

Maximize value for money using special team discounts:

- **10% discount – 2 delegates**
- **15% discount – 3 delegates**
- **20% discount – 4+ delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates.

For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com

**Start-up, academic and not-for-profit rates are subject to organizer approval. Please note we have a special rate of \$699 for students and post-docs. To find out more information, please email: register@hansonwade.com Full T&Cs apply. Visit the website for full eligibility criteria.*



VENUE

Aloft Boston Seaport District
401-403 D Street
Boston, Massachusetts 02210

For further information or assistance, please visit
www.marriott.com/hotels/travel/bosal-aloft-boston-seaport-district

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH